|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,567.00 JPY | +0.27% |
|
-0.16% | +1.58% |
| 12-11 | Amgen Inc. Announces FDA Approval Of UPLIZNA For Adults With Generalized Myasthenia Gravis | CI |
| 12-11 | Kyowa Kirin Co Ltd - Notice regarding change in management structure (CEO succession) | RE |
| Capitalization | 1,344B 8.5B 7.33B 6.82B 6.35B 11.83B 772B 12.73B 78.5B 30.95B 368B 31.89B 31.23B | P/E ratio 2025 * |
24.1x | P/E ratio 2026 * | 19.2x |
|---|---|---|---|---|---|
| Enterprise value | 1,135B 7.18B 6.19B 5.76B 5.36B 9.99B 651B 10.75B 66.28B 26.13B 311B 26.92B 26.37B | EV / Sales 2025 * |
2.35x | EV / Sales 2026 * | 2.21x |
| Free-Float |
41.96% | Yield 2025 * |
2.34% | Yield 2026 * | 2.37% |
| 1 day | +0.27% | ||
| 1 week | -0.16% | ||
| Current month | +1.58% | ||
| 1 month | +0.16% | ||
| 3 months | +15.03% | ||
| 6 months | +1.22% | ||
| Current year | +1.58% |
| 1 week | 2,520 |  | 2,610 |
| 1 month | 2,478.5 | | 2,610 |
| Current year | 2,478.5 | | 2,610 |
| 1 year | 2,025 | | 2,706 |
| 3 years | 2,025 | | 3,350 |
| 5 years | 2,025 | | 4,240 |
| 10 years | 1,412 | | 4,240 |
| Manager | Title | Age | Since |
|---|---|---|---|
Masashi Miyamoto
CEO | Chief Executive Officer | 66 | 2011-03-31 |
Abdul Mullick
PSD | President | - | 2025-03-27 |
| Director of Finance/CFO | - | 1986-03-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Masashi Miyamoto
CHM | Chairman | 66 | 2025-02-28 |
Takashi Oyamada
BRD | Director/Board Member | 70 | 2021-02-28 |
Yoshihisa Suzuki
BRD | Director/Board Member | 70 | 2022-02-28 |
| Name | Varia. Jan 1. | Weight | AuM | |
|---|---|---|---|---|
 | +2.59% | 2.22% | 27 M€ | |
| -.--% | 1.51% | 0 M€ | |
| +7.89% | 0.44% | 10 M€ |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +0.27% | -0.16% | +12.34% | -9.58% | 8.5B | |
| +0.85% | +1.33% | -8.03% | -34.01% | 65.56B | |
| -0.85% | -1.74% | +29.95% | +39.57% | 8.37B | |
| +0.67% | -3.76% | +9.75% | +66.99% | 6.4B | |
| -0.28% | -4.77% | -19.48% | +113.36% | 5.47B | |
| -1.05% | -8.18% | +179.31% | +37.88% | 4.06B | |
| -0.70% | -2.10% | -10.96% | -20.57% | 3.01B | |
| -0.52% | -2.17% | +32.49% | +24.75% | 2.87B | |
| +1.89% | +3.79% | +56.78% | +41.82% | 2.77B | |
| Average | +0.03% | -1.40% | +31.35% | +28.91% | 11.89B | |
| Weighted average by Cap. | +0.48% | +0.08% | +6.83% | -6.10% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 482B 3.05B 2.63B 2.45B 2.28B 4.24B 277B 4.57B 28.16B 11.1B 132B 11.44B 11.2B | 508B 3.22B 2.77B 2.58B 2.4B 4.47B 292B 4.81B 29.69B 11.71B 139B 12.06B 11.81B |
| Net income | 56.04B 355M 306M 285M 265M 493M 32.17B 531M 3.27B 1.29B 15.35B 1.33B 1.3B | 70.19B 444M 383M 356M 332M 618M 40.3B 665M 4.1B 1.62B 19.22B 1.67B 1.63B |
| Net Debt | -209B -1.32B -1.14B -1.06B -989M -1.84B -120B -1.98B -12.22B -4.82B -57.3B -4.96B -4.86B | -220B -1.39B -1.2B -1.12B -1.04B -1.94B -126B -2.08B -12.85B -5.07B -60.22B -5.22B -5.11B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-01-16 | 2,567.00 ¥ | +0.27% | 1,084,200 |
| 26-01-15 | 2,560.00 ¥ | -0.49% | 1,039,100 |
| 26-01-14 | 2,572.50 ¥ | +0.55% | 813,300 |
| 26-01-13 | 2,558.50 ¥ | -0.49% | 1,169,200 |
| 26-01-09 | 2,571.00 ¥ | +0.18% | 1,152,100 |
Delayed Quote Japan Exchange, January 16, 2026 at 01:30 am
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- 4151 Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition